Discontinuation study of nilotinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop study in Japan adult leukemia study group
Latest Information Update: 30 Nov 2022
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms JALSG-D-STOP216
- 29 Nov 2022 Planned End Date changed from 30 Nov 2021 to 30 Sep 2022.
- 14 Dec 2021 Results assessing immune effects before and after TFR phase in two Japanese discontinuation trials of second-generation TKIs (JALSG N-STOP216 and D-STOP216), presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association